Labreportnew

NAME : Mrs.
MONISHA SAMPLE TYPE : 10085038
Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM
SPECIMEN
PATIENT
ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023
REF BY Dr. : - REPORT D/T. : 29/May/2023 05:11PM
PERM NO : PRINT D/T. : 29/May/2023 05:11PM
DEPARTMENT OF HAEMATOLOGY
REAL IMAGING MASTER CHECK
Test Result Units Biological Reference Interval
COMPLETE BLOOD COUNT

T.L.C 10,900 Cell/Cumm 4000 - 11000
Method : Eletronic Impedance
R.B.C. COUNT 4.87 Millions/cmm 3.8 - 5.8
Method : Hydro Dynamic Focusing
HAEMOGLOBIN 12.6 g/dl 12.0 - 16.0
Method : SLS Hb Analysis
P.C.V. 40.90 % 35 - 50
Method : RBC Pulse height detection
M.C.V. 84.00 fL 78 - 94
Method : Calculated
M.C.H 28.50 pg 27 - 32
Method : Calculated
M.C.H.C 34.00 % 32 - 38
Method : Calculated
PLATELET 2.75 10^5/uL 1.5 - 4.5
Method : Hydro Dynamic Focusing
R.D.W (CV) 13.90 % 11.5 - 14.5
Method : Calculated
Differential Cell Count
NEUTROPHILS 60 % 40 - 75
Method : Manual
LYMPHOCYTES 31 % 20 - 40
Method : Manual
MONOCYTES 06 % 2 - 10
Method : Manual
EOSINOPHILS 03 % 1-6
# Final Report Authenticated On : 29/May/2023 05:13PM

Requested On : 28/May/2023 10:06AM
Page 1 of 13
Print DateTime : 29/May/2023 6:49 PM
N.B. : The results relate to the sample tested only. Partial reproduction of the report is prohibited. Not valid for medico-legal Purpose.
NAME : Mrs. MONISHA SAMPLE TYPE : 10085038
SPECIMEN
PATIENT
Method : Manual
BASOPHILS 00 % 0-2
Method : Manual
SAMPLE TYPE :EDTA

Page 2 of 13
SPECIMEN
PATIENT
HbA1c (Glycosylated Haemoglobin) 9.00 % < 5.7

Method : HPLC
SAMPLE TYPE :EDTA
Interpretation
-------------------------------------------------------------------------------
| As per American Diabetes Association (ADA) |
|-------------------------------------------------------------------------------|
| Reference Group | HbA1c in % |
|-------------------------------|-----------------------------------------------|
| Non diabetic adults >=18 years | <5.7 |
|-------------------------------|-----------------------------------------------|
| At risk (Prediabetes) | 5.7 - 6.4 |
|-------------------------------|-----------------------------------------------|
| Diagnosing Diabetes | >= 6.5 |
|-------------------------------|-----------------------------------------------|
*** End of Report ***

Page 3 of 13
SPECIMEN
PATIENT
DEPARTMENT OF BIOCHEMISTRY
BLOOD SUGAR (FASTING)

PLASMA GLUCOSE FASTING 152.00 mg/dl 70 - 100
Method : Hexokinase
SAMPLE TYPE :Fluoride-F
PHOSPHORUS 3.90 mg/dl 2.7 - 4.1

Method : SLS Hb Analysis
SAMPLE TYPE :SERUM

Page 4 of 13
SPECIMEN
PATIENT
LIPID PROFILE
CHOLESTEROL (TOTAL) 234.1 mg/dl 120 - 200
Method : CHOD - POD
TRIGLYCERIDES 160.5 mg/dl < 150
Method : Enz Colorimeric
VLDL 32.10 mg/dl 10.0 - 30.0
Method : Calculated
HDL 34.5 mg/dL 40 - 70
LDL CHOLESTEROL (DIRECT) 167.50 mg/dL 30 - 100
CHOLESTEROL / HDL RATIO 6.79 Ratio 0.0 - 4.97
Method : Calculated
LDL / HDL RATIO 4.86 Ratio 0.00 - 3.55
Method : Calculated
SAMPLE TYPE :SERUM
Read more : Cholesterol Risk Calculator | www.medindia.netindia.net

Page 5 of 13
SPECIMEN
PATIENT
LIVER FUNCTION TEST

BILIRUBIN (TOTAL) 0.63 mg/dl 0.1 - 1.0
Method : Diazo
BILIRUBIN (DIRECT) 0.56 mg/dl 0.0 - 0.6
Method : Diazo
BILIRUBIN (INDIRECT) 0.07 mg/dl
Method : Calculated
S.G.O.T (AST) 53.2 U/L 5.0 - 46.0
Method : IFCC (Without P5P)
S.G.P.T. (ALT) 59.4 U/L 5.0 - 49.0
Method : IFCC (Without P5P)
ALKALINE PHOSPHATASE 117 U/L 42 - 98
Method : Colorimetric assay
TOTAL PROTEIN 6.24 gm/dl 6.1 - 8.0
Method : BIURET
ALBUMIN 4.32 gm/dl 3.6 - 5.3
Method : BCG
GLOBULIN 1.92 g/dl 2.0 - 3.5
Method : Calculated
A/G Ratio 2.25 Ratio 1.0 - 2.0
Method : ration
SAMPLE TYPE :SERUM
NOTE :
1.In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of increased AST,
ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.

Page 6 of 13
SPECIMEN
PATIENT
2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic Hepatitis,
Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT ratio>1 is highly suggestive of
advanced liver fibrosis.
3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD, Enhanced
liver fibrosis (ELF) test may be used to evaluate liver fibrosis.
4. In a patient with Chronic Liver disease, AFP can be used to assess risk for development of Hepatocellular Carcinoma.

Page 7 of 13
SPECIMEN
PATIENT
KIDNEY FUNCTION TEST

UREA 28.23 mg/dl 16.6 - 48.5
Method : Urease - GLDH
CREATININE 0.88 mg/dl 0.5 - 1.2
Method : Alkaline Picrate
URIC ACID 4.96 mg/dl 2.4 - 5.7
Method : Uricase
SODIUM 140.00 mEq/L 136 - 150
Method : Ion Selective Electrode
POTASSIUM 5.40 mEq/L 3.5 - 5.5
Method : Ion Selective Electrode
CALCIUM 8.29 mg/dl 8.6 - 10.2
Method : N-methyl BAPTA
SAMPLE TYPE :SERUM
** IRON PROFILE
IRON-SERUM 86.00 ugm/dL 37.0 - 150.0
Method : Ferrozine
TOTAL IRON BINDING CAPACITY 502.00 ugm/dL 270.0 - 380.0
Method : Ferrozine
Unbound Iron Binding Capacity 416.0
SAMPLE TYPE :SERUM
** SERUM ELECTROLYTE
Sodium 140.00 mEq/L 136 -150
Potasium (K+) 5.40 mEq/L 3.50-5.5
Chloride, serum 101.00 mmol/L 1.12 - 1.35

Page 8 of 13
Authenticated On : 29/May/2023 05:13PM

Page 9 of 13
SPECIMEN
PATIENT
DEPARTMENT OF SEROLOGY
** RHEUMATOID FACTOR (QUALITATIVE)

Rheumatoid Factor NEGATIVE NEGATIVE
Method : Immunoturbidimetric
SAMPLE TYPE :SERUM

Page 10 of 13
SPECIMEN
PATIENT
DEPARTMENT OF IMMUNOASSAY
THYROID PROFILE
T3 1.68 nmol/L 0.8 - 2.2
Method : C.L.I.A.
T4 137.0 nmol/L 64.0 - 140.0
Method : C.L.I.A.
TSH 2.03 uIU/mL 0.35 - 5.50
Method : C.L.I.A.
SAMPLE TYPE :SERUM
Comments
The thyroid-stimulating hormone (TSH) test is often the test of choice for evaluating thyroid function and/or symptoms of a
thyroid disorder,including hyperthyroidism or hypothyroidism.
TSH is produced by the pituitary gland, a tiny organ located below the brain and behind the sinus cavities. It is part of the
body's feedback system to maintain stable amounts of the thyroid hormones thyroxine (T4) and triiodothyronine (T3) in
the blood and to help control the rate at which the body uses energy.
Test is used to:
Diagnose a thyroid disorder in a person with symptoms

Screen newborns for an underactive thyroid
Monitor thyroid replacement therapy in people with hypothyroidism
Monitor anti-thyroid treatment in people with hyperthyroidism
Help diagnose and monitor infertility problems in women

Page 11 of 13
SPECIMEN
PATIENT
** VITAMIN B12 , SERUM 182.00 pg/mL 211 - 960
Method : C.L.I.A.
SAMPLE TYPE :SERUM
COMMENTS :
Vitamin B12, a member of the corrin family of compounds, is implicated in the formation of myelin, and along
with folate, is required for DNA synthesis. The most prominent source of B12 for humans is meat, while
untreated fresh water can also be a source.
Up to 40-50 % of serum corrins may be physiologically inactive B12 analogues. These analogues serve no
useful function and may compete with B12 binding capacity. The archetypical analogue,cobinamide, is not
bound by the primary binding protein specific for ileal B12 uptake.
Megaloblastic Anaemia, characterized by elevated MCV, has been found to be due to B12 deficiency, a major
cause being pernicious Anaemia due to poor B12 uptake resulting to low B12 levels include iron deficiency,
normal near -term pregnancy, vegetarianism, partial gastrectomy, ileal damage, oral contraceptives, parasitic
infestation, pancreatic deficiency, treated epilepsy and advancing age. The correlation of serum B12 levels and

Page 12 of 13
SPECIMEN
PATIENT
** VITAMIN - D3
VITAMIN - D3 55.70 ng/ml 30 - 100
Reference Range :-
Deficiency : < 10 ng/ml

Insufficiency : 10 - 30 ng/ml
Sufficiency : 30 - 100 ng/ml
Toxicity : >100 ng/ml
CLINICAL SIGNIFICANCE:-
Optimal 25(OH)D levels are more than or equal to 30 ng/mL, while levels of 21 to 29 ng/mL indicate vitamin D
insufficiency and levels less than 20 ng/mL indicate deficiency. Vitamin D insufficiency and deficiency may both lead to
elevated PTH levels (secondary hyperparathyroidism), and the most severe forms of deficiency may be associated with
hypocalcemia, hypophosphatemia, and elevated alkaline phosphatase.
High 25(OH)D levels are suggestive of vitamin D toxicity. Expert opinions vary regarding an appropriate toxicity
threshold. Although the Institute of Medicine cites reports of adverse events at 25(OH)D levels more than or equal to 50
ng/mL and recommends relatively low vitamin D intake levels, many experts including the authors of the Endocrine Society
clinical practice guideline disagree with such a low toxicity threshold and assert that vitamin D toxicity only occurs at
25(OH)D levels more than or equal to 150 ng/mL.

Page 13 of 13

Labreportnew

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Labreportnew

Uploaded by

Copyright:

Available Formats

NAME : Mrs.

MONISHA SAMPLE TYPE : 10085038

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 05:11PM

PERM NO : PRINT D/T. : 29/May/2023 05:11PM

COMPLETE BLOOD COUNT

# Final Report Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 05:11PM

PERM NO : PRINT D/T. : 29/May/2023 05:11PM

# Final Report Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 05:12PM

PERM NO : PRINT D/T. : 29/May/2023 05:12PM

HbA1c (Glycosylated Haemoglobin) 9.00 % < 5.7

*** End of Report ***

# Final Report Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 12:57PM

PERM NO : PRINT D/T. : 29/May/2023 12:57PM

BLOOD SUGAR (FASTING)

PHOSPHORUS 3.90 mg/dl 2.7 - 4.1

# Final Report Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 01:01PM

PERM NO : PRINT D/T. : 29/May/2023 01:01PM

Read more : Cholesterol Risk Calculator | www.medindia.netindia.net

# Final Report Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 01:01PM

PERM NO : PRINT D/T. : 29/May/2023 01:01PM

LIVER FUNCTION TEST

# Final Report Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 01:01PM

PERM NO : PRINT D/T. : 29/May/2023 01:01PM

# Final Report Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 01:01PM

PERM NO : PRINT D/T. : 29/May/2023 01:01PM

KIDNEY FUNCTION TEST

# Final Report Authenticated On : 29/May/2023 05:13PM

Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 05:13PM

PERM NO : PRINT D/T. : 29/May/2023 05:13PM

** RHEUMATOID FACTOR (QUALITATIVE)

*** End of Report ***

# Final Report Authenticated On : 29/May/2023 05:13PM

Age/Gender : 46 Y/Female REGISTRATION D/T. : 28/May/2023 08:48AM

ID No./Reg Id : 012305280002 / 79259 COLLECTION D/T. : 28/May/2023

REF BY Dr. : - REPORT D/T. : 29/May/2023 05:13PM

PERM NO : PRINT D/T. : 29/May/2023 05:13PM

* End of Report *

* End of Report *

* End of Report *